Form 4: Vaxcyte Executive Trades Shares Under 10b5-1 Plan

Vaxcyte, Inc. reports a Form 4 filing detailing stock transactions by SVP, Finance & CAO Elvia Cowan, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Elvia Cowan, SVP, Finance & CAO of Vaxcyte, Inc., reported transactions on April 7, 2026.
• Cowan acquired 3,000 shares of common stock at a price of $25.92 per share.
• Concurrently, Cowan disposed of 3,000 shares of common stock at a price of $60 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 8, 2025.
• Following these transactions, Cowan beneficially owns 28,975 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves stock transactions by a senior executive, the execution under a pre-established 10b5-1 plan mitigates concerns about insider trading and suggests a planned approach to personal financial management rather than a reaction to material non-public information.

Positives

• The acquisition of shares at a lower price ($25.92) than the sale price ($60) indicates a profitable transaction for the reporting person.
• The use of a Rule 10b5-1 plan suggests pre-planned and potentially diversified trading strategies, which can be viewed positively for corporate governance.
• The reporting person continues to hold a significant number of shares (28,975) after the reported transactions.

Negatives

• The disposal of 3,000 shares at a higher price indicates a reduction in the reporting person's direct beneficial ownership of the company's stock.
• The sale of shares, even under a 10b5-1 plan, could be interpreted by the market as a signal of reduced confidence by management, although the plan is designed to mitigate insider trading concerns.

Risks

• The filing does not explicitly mention any new risks or challenges.
• The sale of shares by a key executive, even under a pre-arranged plan, could be perceived negatively by investors, potentially impacting share price if interpreted as a lack of confidence.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports past transactions by an executive.

Management Comments

• The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.
• 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by Vaxcyte's SVP of Finance is a common practice for executives to manage their stock holdings in a manner that complies with insider trading regulations, especially in the biotechnology sector where stock price can be volatile.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the sale of shares by an executive, even under a 10b5-1 plan, with varying degrees of concern, potentially influencing short-term trading sentiment.
• Employees: The executive's stock transactions may indirectly influence employee morale and perception of company leadership.
• Creditors: No direct impact anticipated from this filing.

Next Steps

• Continue to monitor future Form 4 filings for any additional transactions by Vaxcyte executives.
• Observe the company's stock performance and any related news or announcements that may provide context for executive trading activities.

Key Dates

Keywords

Vaxcyte, PCVX, Form 4, Insider Trading, 10b5-1 Plan, Stock Transaction, Beneficial Ownership, Executive Compensation, Securities Trading